Nichole Tucker

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In an interview with Targeted Oncology, Michael Chuong, MD, discussed how 5 fractions of ablative radiation therapy compare with 15-25 fractions for the treatment of locally advanced pancreatic cancer.

In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.

With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.

The impressive POSEIDON clinical trial results have led to the FDA approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of metastatic non–small cell lung cancer.

The FDA has advised ADC Therapeutics that a randomized phase 3 confirmatory study is needed to support a future FDA approval for camidanlumab tesirine as treatment of relapsed or refractory Hodgkin lymphoma.

Ipsen plans to seek FDA approval for the NALIRIFOX regimen based on positive results from the phase 3 NAPOLI 3 clinical trial.

Results from bemarituzumab in the phase 2 FIGHT study hint that FGFR2b may be a new target of interest in gastric cancer.

Positive Study 16113 results have led the FDA to grant approval to to cemiplimab in combination with chemotherapy for the treatment of patients with advanced non–small cell lung cancer.

Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.

After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.

The newly launched phase 2 LenCabo study of lenvatinib with everolimus vs cabozantinib for the second- or third-line treatment of metastatic renal cell carcinoma.

During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc

Despite halting the development of SRF388, the developer announces positive phase 1 efficacy and progress in a phase 2 study of SRF388 in combination with pembrolizumab.

In an interview with Targeted Oncology, Jennifer Hong Kuo, MD, discussed the use of radiofrequency ablation to treat thyroid nodules and how research from Columbia University will guide further research around this topic

Following positive results and FDA action on pidnarulex in BRAC 1/2-positive ovarian cancer, a phase 1 study is exploring the agent in metastatic castration-resistant prostate cancer, in combination with talazoparib.

Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.

Following JAK inhibitor therapy, multiple agents are showing the ability to reduce symptoms and spleen volume while improving survival in patient with myelofibrosis.

Positive efficacy and safety results from the phase 3 EPCORE™ NHL-1 trial have lead to an FDA application for approval of epcoritamab to treat relapsed or refractory large B-cell lymphoma.

Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

A progression-free survival advantage and trend toward overall survival benefit has been demonstrated in the CAPItello-291 study of capivasertib and fulvestrant for the treatment of hormone receptor-positive, HER2-low or negative locally advanced or metastatic breast cancer.

The risk of progression or death in post-menopausal patients with estrogen receptor-positive locally advanced or metastatic breast cancer was reduced with camizestrant in the SERENA-2 study.

In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, and Chris Fine, MD, FACC, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed research around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.

In patients with completely resected stage IIB or IIC melanoma, use of adjuvant nivolumab achieved a 58% reduction in the risk of recurrence or death.

A suspected unexpected serious adverse reaction to seclidemstat led the developer to pause a phase 1/2 evaluating the agent in patients with Ewing and FET-rearranged sarcoma.

Treatment with the investigational Bruton’s tyrosine kinase inhibitor, pirtobrutinib, will be compared with ibrutinib treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in a phase 2 study.